• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$38.64 $0.13 (0.34%)

REAL-TIME: Last trade at

BioMarin Pharmaceutical

NASDAQ:BMRN

Jump to this page for:

Related Resources

8 Stocks Rising on Big Volume

5/21/2012 by TheStreet.com

BioMarin price target raised to $44 from $40 at Leerink

5/18/2012 by Theflyonthewall.com

5 Stocks Hit 52-Week Highs

5/16/2012 by TheStreet.com

Rodman & Renshaw Capital Group Announces 1st Quarter 2012 Financial Results

5/15/2012 by Business Wire

Leerink's biotech analyst discusses BMN-110 GALNs on a conference call

5/14/2012 by Theflyonthewall.com

BioMarin price target raised to $49 from $45 at Citigroup

5/14/2012 by Theflyonthewall.com

Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases% Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation

5/10/2012 by PR Newswire

BioMarin appoints Dan Spiegelman as CFO

5/8/2012 by Theflyonthewall.com

BioMarin Appoints Dan Spiegelman as Executive Vice President and Chief Financial Officer

5/8/2012 by GlobeNewswire

JP Morgan's biotech analysts hold a conference call on orphan drug coverage

5/8/2012 by Theflyonthewall.com

Wider Loss at BioMarin - Analyst Blog

4/30/2012 by Zacks Investment Research

Wider Loss at BioMarin

4/30/2012 by Zacks Equity Research Analyst Blog

BioMarin Pharmaceutical's CEO Discusses Q1 2012 Results - Earnings Call Transcript

4/27/2012 by Seeking Alpha

BioMarin Pharma (BMRN) Misses Q1 EPS by 7c; Raises FY12 Sales Guidance

4/26/2012 by StreetInsider.com

BioMarin mantains 2012 adjusted net cash flow useage at negative $30M-$40M

4/26/2012 by Theflyonthewall.com

BioMarin maintains 2012 adjusted EBITDA view of $15M-$25M

4/26/2012 by Theflyonthewall.com

BioMarin maintains 2012 SG&A guidance of $195M-$205M

4/26/2012 by Theflyonthewall.com

BioMarin raises R&D expense view to $265M-$275M from $255M-$265M

4/26/2012 by Theflyonthewall.com

BioMarin cuts 2012 revenue view to $475M-$510M, consensus $487.87M

4/26/2012 by Theflyonthewall.com

BioMarin reports Q1 EPS (21c), consensus (14c)

4/26/2012 by Theflyonthewall.com

BioMarin Announces First Quarter 2012 Financial Results

4/26/2012 by GlobeNewswire

Biotechnology And Drugs Stocks To Watch Ahead Of Earnings (Part 2)

4/18/2012 by Seeking Alpha

UPDATE - UBS Initiates Coverage on BioMarin (BMRN) with a Buy; Accumulate on Pullback

4/12/2012 by StreetInsider.com

BioMarin initiated with a Buy at UBS

4/12/2012 by Theflyonthewall.com

BioMarin To Host First Quarter 2012 Financial Results Conference Call And Webcast On Thursday, April 26 At 5:00 P.m. ET

4/6/2012 by Biocompare

Piper Jaffray's biotech and specialty pharma analysts hold a conference call

4/5/2012 by Theflyonthewall.com

BioMarin to Host First Quarter 2012 Financial Results Conference Call and Webcast on Thursday, April 26 at 5:00 p.m. ET

4/5/2012 by GlobeNewswire

Bullish on Biotechs

4/4/2012 by CNBC Video

How Much Further Can Rare Diseases Carry BioMarin?

3/29/2012 by Seeking Alpha

Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher's and Niemann-Pick Poised to Supersede Existing Therapies

3/28/2012 by PR Newswire

4 Biotech ETFs for a Healthy Portfolio

3/27/2012 by InvestorPlace

Canaccord Genuity Starts BioMarin Pharmaceutical Inc. (BMRN) at Buy

3/26/2012 by StreetInsider.com

Brean Murray Upgrades Biomarin Pharma (BMRN) To 'Buy' On GALNS Late-Study Trial Timing

3/19/2012 by iStockAnalyst

Brean Murray Carret & Co. Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Buy; Increased Confidence in GALNS Phase 3 Trial

3/19/2012 by StreetInsider.com

BioMarin upgraded to Buy from Hold at Brean Murray

3/19/2012 by Theflyonthewall.com

BioMarin Raised to Neutral - Analyst Blog

3/14/2012 by NASDAQ

BioMarin Raised to Neutral - Analyst Blog

3/14/2012 by Zacks Investment Research

BioMarin Raised to Neutral

3/14/2012 by Zacks Equity Research Analyst Blog

BioMarin Completes Enrollment For Phase 3 Trial For GALNS For The Treatment Of MPS IVA

3/9/2012 by Biocompare

BioMarin Completes Enrollment for Phase 3 Trial for GALNS for the Treatment of MPS IVA

3/8/2012 by GlobeNewswire
See More Articles...